Published • loading... • Updated
LEO Pharma Receives Positive CHMP Opinion Recommending Anzupgo® (Delgocitinib) Cream for Adolescents with Moderate to Severe Chronic Hand Eczema in the EU
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
LEO Pharma Receives Positive CHMP Opinion Recommending Anzupgo® (Delgocitinib) Cream for Adolescents with Moderate to Severe Chronic Hand Eczema in the EU
LEO Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label expansion for Anzupgo® (delgocitinib) cream to include adolescents aged 12 to 17 years with moderate to severe chronic hand eczema. [LEO Pharma] Press Release
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
